June, 2024
June 2024
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Sergio Cifuentes Canaval: KN 189 and 407 – Pooled Analysis of Outcomes
May 19, 2024, 14:53

Sergio Cifuentes Canaval: KN 189 and 407 – Pooled Analysis of Outcomes

Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared on LinkedIn:

“KN 189 and 407: Pooled Analysis of Outcomes After 5 Years of Follow-Up of Pembrolizumab + CHT for mNSCLC with PDL1 < 1%:

There is an urgent need in NSCLC treatment with PD-1 inhibitor less than < 1% without drivers mutations, Pembrolizumab has shown efficacy in combination with chemotherapy in this population.

Methods:
In this pooled analysis, data from four phase 3 studies were included: KEYNOTE-189, KEYNOTE-407, the Japanese extension of KEYNOTE-189, and the Chinese extension of KEYNOTE-407. Patients with metastatic NSCLC without EGFR or ALK alterations received pembrolizumab or placebo along with different chemotherapy regimens. PD-L1 expression was assessed using immunohistochemistry (IHC).

Results:
OS: Pembro + CHT: improved OS, HR 0.64.
PFS: HR 0.66 for the combination of Pembro + CHT.
5-Year OS Rates: 12.5% (pembrolizumab + chemotherapy) vs. 9.3% (CHT alone).

Conclusion:
With 5 years of follow-up, pembrolizumab + chemotherapy continues to demonstrate significant and durable survival improvements in patients with metastatic NSCLC and PD-L1 TPS <1%, with a significant reduction of the risk of death or progression in 35% aprox.”

Visit the article website.
Source: Sergio Cifuentes Canaval/LinkedIn